Drug corporations square measure seemingly to launch seven
"blockbuster" medication in 2016, every with $1 billion-plus annual
sales potential, semiconductor diode by new treatments for disease and HIV, in
keeping with a Thomson Reuters analysis.
The assessment suggests that the prescription drugs trade is
on the right track for an additional productive year, though not nearly as good
as 2015, that saw the arrival of eleven new blockbusters.
The two high hits of 2016 square measure tipped to be
Intercept Pharmaceuticals' (ICPT.O) chronic disease drug obeticholic acid, with
a agreement sales forecast of $2.6 billion in 2020, and Gilead Sciences'
(GILD.O) new fastened dose HIV drug emtricitabine and tenofovir alafenamide, on
$2.0 billion.
Other merchandise expected to launch this year with forecast
sales higher than $1 billion in 2020 embody a brand new hepatitis C drug from
Merck (MRK.N) and a leukaemia medication from AbbVie (ABBV.N), in keeping with
the annual "Drugs to Watch" report.
Two keenly expected Roche (ROG.VX) drugs, every with
forecast sales of around $3 billion, don't seem to be on list as a result of
it's unclear if atezolizumab for cancer and ocrelizumab for induration are
going to be commercially accessible this year or next.
No comments:
Post a Comment